Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

From a certain high-heeled Mouse to the tiny version of our favorite candy, just the idea of "mini" is psychologically ...

Stroke survivors were 44% more likely to have an excellent outcome (modified Rankin score 0-1) after 90 days if they received the tenecteplase injection and standard care after clot removal ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after succe ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...